Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Synthetica Closes A Round to Support Living Bacterial Therapeutics

publication date: Jul 30, 2024

Shenzhen Synthetica Pioneering closed a Series A round to develop novel living bacterial therapeutics. Founded in 2023, the company specializes in genetic circuit engineering and precise control of genes and payloads to treat various diseases, especially solid tumor cancers. Synthetica is a spin-off from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences that uses synthetic biology techniques to engineer novel living bacterial therapeutics. The Series A funding was led by Boehringer Ingelheim Venture Fund and Temasek. The funding will be used to fast-track Synthetica's oncolytic bacterial candidates into clinical trials. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here